Biotech Co. Human Genome Rejects $2.6B Bid From GSK
Gene-targeting drug developer Human Genome Sciences Inc. on Thursday rejected an unsolicited $2.59 billion bid from GlaxoSmithKline PLC, but a cozy relationship between the companies could still result in a takeover,...To view the full article, register now.
Already a subscriber? Click here to view full article